{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:56:57Z","timestamp":1790384217591,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T00:00:00Z","timestamp":1576800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Endoscopic and histological gut inflammation are present in half of patients with ankylosing spondylitis [AS] or spondyloarthritis [SpA]. We performed a systematic literature review on the use of faecal calprotectin [FC] in patients with rheumatic diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Searches of the PubMed, Web of Science, and Cochrane Library databases were performed up to September 2019 to identify all studies including adult patients with confirmed diagnosis of SpA or AS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seven studies met the inclusion criteria: six prospective observational studies and one retrospective observational study. Study populations consisted of SpA patients in four studies and AS patients in three studies. In six studies, an ELISA test was used for FC levels and in one case, a semi-quantitative assay was adopted. In all included studies, patients with SpA or AS had elevated FC levels, ranging from 21.2% to 70.7% of patients. In six studies, patients with increased FC levels had macroscopic mucosal inflammation, ranging from 11% to 80% of cases. Four studies highlighted the presence of microscopic alterations in patients with high FC levels, ranging from 41.7% to 100% of patients. An FC cut-off level predicting the inflammatory bowel disease [IBD] occurrence was found in two studies: 266 mg\/kg and 132 mg\/kg, with sensitivity and specificity of 100%, 78.7% and 66.7%, 76.9%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Faecal calprotectin is a useful and non-invasive marker to predict IBD in patients with SpA or AS. Gut histological and macroscopic mucosal inflammation were found in up to 100% and 80% of rheumatological patients with increased FC levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjz205","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T20:16:52Z","timestamp":1576613812000},"page":"688-693","source":"Crossref","is-referenced-by-count":38,"title":["Faecal Calprotectin for the Diagnosis of Bowel Inflammation in Patients With Rheumatological Diseases: A Systematic Review"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-0531","authenticated-orcid":false,"given":"Marine","family":"Fauny","sequence":"first","affiliation":[{"name":"Rheumatology Department, University Hospital of Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"Department of Gastroenterology and Inserm NGERE U1256, University of Lorraine, Nancy University Hospital, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6102-6579","authenticated-orcid":false,"given":"Stefanos","family":"Bonovas","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Netter","sequence":"additional","affiliation":[{"name":"Ing\u00e9nierie Mol\u00e9culaire et Ing\u00e9nierie Articulaire [IMoPA]. UMR-7365 CNRS, University of Lorraine and University Hospital of Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"},{"name":"IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center- IRCCS-, Rozzano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Loeuille","sequence":"additional","affiliation":[{"name":"Rheumatology Department, University Hospital of Nancy, Nancy, France"},{"name":"Ing\u00e9nierie Mol\u00e9culaire et Ing\u00e9nierie Articulaire [IMoPA]. UMR-7365 CNRS, University of Lorraine and University Hospital of Nancy, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Inserm NGERE U1256, University of Lorraine, Nancy University Hospital, Vandoeuvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"2021040703075672500_CIT0001","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","article-title":"Spondyloarthritis","volume":"377","author":"Dougados","year":"2011","journal-title":"Lancet"},{"key":"2021040703075672500_CIT0002","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"key":"2021040703075672500_CIT0003","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"2021040703075672500_CIT0004","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"key":"2021040703075672500_CIT0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13075-017-1223-2","article-title":"A longitudinal study of fecal calprotectin and the development of inflammatory bowel disease in ankylosing spondylitis","volume":"19","author":"Klingberg","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2021040703075672500_CIT0006","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10067-016-3261-6","article-title":"ASAS classification criteria for axial spondyloarthritis: time to modify","volume":"35","author":"Akkoc","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2021040703075672500_CIT0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2021040703075672500_CIT0008","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD. Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"2021040703075672500_CIT0009","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/rheumatology\/XXVII.suppl_2.95","article-title":"Ileocolonoscopic findings in seronegative spondylarthropathies","volume":"27[Suppl 2]","author":"Mielants","year":"1988","journal-title":"Br J Rheumatol"},{"key":"2021040703075672500_CIT0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/03009749709065722","article-title":"Ileocolonoscopic and histologic studies of Korean patients with ankylosing spondylitis","volume":"26","author":"Lee","year":"1997","journal-title":"Scand J Rheumatol"},{"key":"2021040703075672500_CIT0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/art.1780370105","article-title":"High frequency of silent inflammatory bowel disease in spondylarthropathy","volume":"37","author":"Leirisalo-Repo","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2021040703075672500_CIT0012","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2012-202135","article-title":"Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model","volume":"72","author":"Van Praet","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021040703075672500_CIT0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021040703075672500_CIT0014","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1053\/gast.1996.v110.pm8964393","article-title":"Long-term evolution of gut inflammation in patients with spondyloarthropathy","volume":"110","author":"De Vos","year":"1996","journal-title":"Gastroenterology"},{"key":"2021040703075672500_CIT0015","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13075-016-1093-z","article-title":"Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis","volume":"18","author":"de Winter","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2021040703075672500_CIT0016","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021040703075672500_CIT0017","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/rheumatology\/keu388","article-title":"Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS","volume":"54","author":"Essers","year":"2015","journal-title":"Rheumatology [Oxford]"},{"key":"2021040703075672500_CIT0018","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.3748\/wjg.v25.i18.2162","article-title":"Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment","volume":"25","author":"Fragoulis","year":"2019","journal-title":"World J Gastroenterol"},{"key":"2021040703075672500_CIT0019","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/00365521.2011.648953","article-title":"Calprotectin in ankylosing spondylitis\u2014frequently elevated in feces, but normal in serum","volume":"47","author":"Klingberg","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"2021040703075672500_CIT0020","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365521.2014.987809","article-title":"Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease","volume":"50","author":"Sipponen","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"2021040703075672500_CIT0021","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/gut.2008.170019","article-title":"Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage","volume":"58","author":"Foell","year":"2009","journal-title":"Gut"},{"key":"2021040703075672500_CIT0022","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.cgh.2015.05.038","article-title":"Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis","volume":"13","author":"Theede","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021040703075672500_CIT0023","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.acc.2018.07.005","article-title":"Fecal calprotectin","volume":"87","author":"Ayling","year":"2018","journal-title":"Adv Clin Chem"},{"key":"2021040703075672500_CIT0024","first-page":"71","article-title":"Fecal calprotectin is associated with disease activity in patients with ankylosing spondylitis","volume":"16","author":"Duran","year":"2016","journal-title":"Bosn J Basic Med Sci"},{"key":"2021040703075672500_CIT0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1136\/annrheumdis-2015-208025","article-title":"Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis","volume":"75","author":"Cypers","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2021040703075672500_CIT0026","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/rheumatology\/key427","article-title":"Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort","volume":"58","author":"Olofsson","year":"2019","journal-title":"Rheumatology [Oxford]"},{"key":"2021040703075672500_CIT0027","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions.","author":"Higgins","year":"2011"},{"key":"2021040703075672500_CIT0028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021040703075672500_CIT0029","doi-asserted-by":"crossref","first-page":"R261","DOI":"10.1186\/ar4106","article-title":"Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study","volume":"14","author":"Matzkies","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2021040703075672500_CIT0030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/03009742.2017.1299216","article-title":"Faecal calprotectin detects subclinical bowel inflammation and may predict treatment response in spondyloarthritis","volume":"47","author":"\u00d8stg\u00e5rd","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2021040703075672500_CIT0031","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3899\/jrheum.161216","article-title":"Detection of Crohn disease in patients with spondyloarthropathy: the SpACE capsule study","volume":"45","author":"Kopylov","year":"2018","journal-title":"J Rheumatol"},{"key":"2021040703075672500_CIT0032","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.arcmed.2019.04.003","article-title":"Fecal calprotectin, gut inflammation and spondyloarthritis","volume":"50","author":"Simioni","year":"2019","journal-title":"Arch Med Res"},{"key":"2021040703075672500_CIT0033","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1053\/j.gastro.2003.08.035","article-title":"Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis","volume":"125","author":"Bjarnason","year":"2003","journal-title":"Gastroenterology"},{"key":"2021040703075672500_CIT0034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/1744666X.2017.1285700","article-title":"Calprotectin and spondyloarthritis","volume":"13","author":"Wendling","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"2021040703075672500_CIT0035","article-title":"The Newcastle-Ottawa Scale for assessing the quality of nonrandomised studies in meta-analyses.","author":"Wells","year":"2009"},{"key":"2021040703075672500_CIT0036","first-page":"510","article-title":"Silent Crohn\u2019s disease","volume":"10","author":"Binion","year":"2014","journal-title":"Gastroenterol Hepatol [N Y]"},{"key":"2021040703075672500_CIT0037","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease [STRIDE]: determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"2021040703075672500_CIT0038","doi-asserted-by":"crossref","first-page":"c3369","DOI":"10.1136\/bmj.c3369","article-title":"Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis","volume":"341","author":"van Rheenen","year":"2010","journal-title":"BMJ"},{"key":"2021040703075672500_CIT0039","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/ibd.21571","article-title":"Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience","volume":"17","author":"Long","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2021040703075672500_CIT0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/gutjnl-2017-315545","article-title":"Comparison of different histological indexes in the assessment of UC activity and their accuracy regarding endoscopic outcomes and faecal calprotectin levels","volume":"68","author":"Magro","year":"2019","journal-title":"Gut"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjz205\/31709374\/jjz205.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/688\/36939095\/eccojc_14_5_688.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/14\/5\/688\/36939095\/eccojc_14_5_688.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T03:08:19Z","timestamp":1617764899000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/14\/5\/688\/5681702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,12,20]]},"published-print":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz205","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2019,12,20]]}}}